The use of engineered immunocytokine PD-1-IL2v in combination with anti-PD-L1 overcomes tumor immunity resistance and improves therapeutic efficacy both by reprogramming immunosuppressive TAMs and enhancing T cell receptor immune repertoire diversity (95). Here, CD274 is linked to neoplasm.